Quantitative assessment of drug treatment side effects in children with idiopathic thrombocytopenic purpura (ITP)
Buchanan GR, Adix L, Klaassen R, et al. Quantitative assessment of drug treatment side effects in children with idiopathic thrombocytopenic purpura (ITP). Blood 2004;104:3030.
Validity, Reliability, and Responsiveness of a New Measure of Health-Related Quality of Life in Children with Immune Thrombocytopenic Purpura: The Kids' ITP Tools
DOI 10.1016/j.jpeds.2007.01.037, PII S0022347607000996
Klaassen RJ, Blanchette VS, Barnard D, et al. Validity, reliability, and responsiveness of a new measure of health-related quality of life in children with immune thrombocytopenic purpura: The Kids' ITP Tools. J Pediatr 2007;150:510-515. (Pubitemid 46602329)
A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP)
DOI 10.1002/pbc.20830
O'Brien SH, Ritchey AK, Smith KJ. A cost-utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP). Pediatr Blood Cancer 2007;48:173-180. (Pubitemid 44958274)
Development of disease-specific health-related quality-of-life instruments for children with immune thrombocytopenic purpura and their parents
DOI 10.1097/00043426-200301000-00011
Barnard D, Woloski M, Feeny D, et al. Development of disease-specific health-related quality-of-life instruments for children with immune thrombocytopenic purpura and their parents. J Pediatr Hematol Oncol 2003;25:56-62. (Pubitemid 36070965)